復星醫藥(02196.HK)附屬公司組基金募資50億元人民幣
復星醫藥(02196.HK)公布,與其他附屬公司復鑫深耀、復星醫藥(深圳)及復健基金管理公司與其他7方投資人訂立目標基金合夥協議,計劃募集50億元(人民幣,下同)資金。三間附屬公司合出資約15億元,其他投資人合共出資35億元。目標基金設立後,將成為復星醫藥之聯營企業。
基金將以深圳為重心,投資生物醫藥、細胞和基因等領域 。,其中投資於生物醫藥領域的金額不低於基金可投資金額的70%。此外,除經合夥人大會同意,基金對單個企業或項目的投資金額不得超過基金認繳出資總額的20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.